Blog

Amicus Therapeutics has been fighting off prospective generics for Galafold®.  Teva settled with Amicus in October 2024, but Aurobindo continued to fight.  The parties recently went to trial, and on November 5, they exchanged their first round of post-trial briefing.  The briefing suggests Amicus faces risk under Section 101 for at least two of its patents as well as prior art risk on all of them.  What do the briefs say?